Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
Status:
Completed
Trial end date:
2020-02-15
Target enrollment:
Participant gender:
Summary
Multi-center, randomized, double-blind, non-inferiority study of cefepime 2 g/AAI101 500 mg
combination compared to piperacillin 4 g/tazobactam 500 mg in a population of adult patients
with cUTI or AP. The study will be conducted in approximately 115 sites located in the EU,
the US, Central, South America and South Africa.
Phase:
Phase 3
Details
Lead Sponsor:
Allecra
Collaborator:
Medpace, Inc.
Treatments:
Cefepime Enmetazobactam Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam